Evacetrapib

Drug / Medication

A potent CETP inhibitor developed by Merck, which showed efficacy in reducing cardiovascular events but was not commercialized due to safety concerns and lack of clear benefit over existing therapies.

Mentioned in 1 video

Videos Mentioning Evacetrapib

#22 – Tom Dayspring Part III of V: reverse cholesterol transport, CETP inhibitors, & apolipoproteins

#22 – Tom Dayspring Part III of V: reverse cholesterol transport, CETP inhibitors, & apolipoproteins

Peter Attia MD

A potent CETP inhibitor developed by Merck, which showed efficacy in reducing cardiovascular events but was not commercialized due to safety concerns and lack of clear benefit over existing therapies.